Cécile Henquell

Dr. Cécile Henquell


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Infectious Diseases Now
Verified
Journal Article
Open access
AMAnna Maisa
Anna Maisa
GSGuillaume Spaccaferri
Guillaume Spaccaferri
LFL. Fournier
L. Fournier
JSJustine Schaeffer
Justine Schaeffer
JDJ. Deniau
J. Deniau
YYY. Yazdanpanah
Y. Yazdanpanah
We aimed to investigate the first Omicron cases detected in France in order to assess case characteristics and provide supporting information on the possible impact of this variant on the healthcare system. A standardized questionnaire was used to collect information from confirmed and probable Omicron cases. Median age of 468 investigated cases was 35 years, 376 were symptomatic (89%); 64% were vaccinated with two doses and 7% had received three doses. Loss of smell and taste were reported by 8.3% and 9% of cases, respectively. Seven cases were hospitalized, three of those were unvaccinated (including two with reported precondition). No admissions to intensive care and no deaths were reported. Our results confirm a mild clinical presentation among the first Omicron cases detected in France and highlight the importance for the national COVID-19 surveillance system to quickly detect and adapt to the emergence of a new variant.

1 April 2012 in Journal of Clinical Virology
Verified
Journal Article
Closed access
CHCécile Henquell
Cécile Henquell
AMAudrey Mirand
Audrey Mirand
ADAnne-Laure Deusebis
Anne-Laure Deusebis
CRChristel Regagnon
Christel Regagnon
CAChristine Archimbaud
Christine Archimbaud
HPHélène Peigue-Lafeuille
Hélène Peigue-Lafeuille

1 August 2009 in Journal of Clinical Virology
Verified
Journal Article
Closed access
CHCécile Henquell
Cécile Henquell
BBBenoît Bœuf
Benoît Bœuf
AMAudrey Mirand
Audrey Mirand
CBCatherine Bacher
Catherine Bacher
OTOusmane Traore
Ousmane Traore
HPHélène Peigue-Lafeuille
Hélène Peigue-Lafeuille

1 July 2004 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
CHCécile Henquell
Cécile Henquell
CCCarole Cartau
Carole Cartau
AAArmand Abergel
Armand Abergel
HLHenri Laurichesse
Henri Laurichesse
CRChristel Regagnon
Christel Regagnon
HPHélÈnE Peigue-Lafeuille
HélÈnE Peigue-Lafeuille
From 1996 to 2002, hepatitis C virus (HCV) typing was prospectively performed for 1,281 unselected HCV-infected and viremic patients, irrespective of their clinical status. Eighty-three patients (6.5%) were coinfected with human immunodeficiency virus (HIV) and HCV. A total of 1,195 strains were identified by a serotype screening (Murex HCV Serotyping 1-6 assay) and/or genotyping (Inno-LiPA HCV II) test. The distribution of HCV types showed an unusually high rate of type 5 (14.2%) that was stable over time and was the third most frequent type, after type 1 (59.1%) and type 3 (15.1%). HCV type 5 was more frequent in patients who were older than 50 ( P = 10 −6 ), but its frequency did not differ significantly by gender ( P = 0.21). Serotyping was performed for 1,160 strains but failed for 30.2% of them. The efficiency depended on HIV status (for HCV-HIV-coinfected patients, half of the strains were untypeable) and HCV type. Genotyping was performed for 428 samples, with an overall efficiency of 99.3%. It failed in three cases, which were subsequently identified as HCV type 2. Serotyping and genotyping results for 39 patients showed discrepancies between the two methods for 4 patients, who had HCV type 2, type 6, or mixed infections. Thus, HCV type 5 may also be encountered frequently in Western countries. Its apparent confinement to a restricted area raises the question of how it emerged and underscores the need for further studies of HCV type prevalence, routes of transmission, pathogenicity, and responses to treatment.

2 March 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
BBBenjamin BONNET
Benjamin BONNET
HCHélène Chabrolles
Hélène Chabrolles
CAChristine Archimbaud
Christine Archimbaud
ABAmélie Brebion
Amélie Brebion
JCJustine Cosme
Justine Cosme
CHCécile Henquell
Cécile Henquell
Clinical trials and real-world evidence on COVID-19 vaccines have shown their effectiveness against severe disease and death but the durability of protection remains unknown. We analysed the humoral and T-cell immune responses in 110 healthcare workers (HCWs) vaccinated according to the manufacturer’s recommended schedule of dose 2 three weeks after dose 1 from a prospective on-going cohort in early 2021, 3 and 6 months after full vaccination with the BNT162b2 mRNA vaccine. Anti-RBD IgG titres were lower in HCWs over 60 years old 3 months after the second dose (p=0.03) and declined in all the subjects between 3 and 6 months with a median percentage change of -58.5%, irrespective of age and baseline comorbidities. Specific T-cell response measured by IGRA declined over time by at least 42% (median) in 91 HCWs and increased by 33% (median) in 17 others. Six HCWs had a negative T-cell response at 6 months. Ongoing follow-up should provide correlates of long-term protection according to the different immune response profiles observed. COVIDIM study was registered under the number NCT04896788 on clinicaltrials.gov.

15 November 2013 in Journal of Virology
Verified
Journal Article
Open access
PDF file
CHCécile Henquell
Cécile Henquell
AMAudrey Mirand
Audrey Mirand
JRJan Richter
Jan Richter
ISIsabelle Schuffenecker
Isabelle Schuffenecker
BBBlenda Böttiger
Blenda Böttiger
JBJean Luc Bailly
Jean Luc Bailly
The aim of this study was to gain insights into the tempo and mode of the evolutionary processes that sustain genetic diversity in coxsackievirus B5 (CVB5) and into the interplay with virus transmission. We estimated phylodynamic patterns with a large sample of virus strains collected in Europe by Bayesian statistical methods, reconstructed the ancestral states of genealogical nodes, and tested for selection. The genealogies estimated with the structural one-dimensional gene encoding the VP1 protein and nonstructural 3CD locus allowed the precise description of lineages over time and cocirculating virus populations within the two CVB5 clades, genogroups A and B. Strong negative selection shaped the evolution of both loci, but compelling phylogenetic data suggested that immune selection pressure resulted in the emergence of the two genogroups with opposed evolutionary pathways. The genogroups also differed in the temporal occurrence of the amino acid changes. The virus strains of genogroup A were characterized by sequential acquisition of nonsynonymous changes in residues exposed at the virus 5-fold axis. The genogroup B viruses were marked by selection of three changes in a different domain (VP1 C terminus) during its early emergence. These external changes resulted in a selective sweep, which was followed by an evolutionary stasis that is still ongoing after 50 years. The inferred population history of CVB5 showed an alternation of the prevailing genogroup during meningitis epidemics across Europe and is interpreted to be a consequence of partial cross-immunity.